Juntendo University, Tokyo, established in 1838.

JU: Juntendo University
MDA: MD Anderson Cancer Center

1. Hamster bone marrow-derived mesenchymal stem cell for intravascular delivery of oncolytic adenovirus Δ24-RGD to hamster glioma.
   (JU / MDA collaboration, ongoing)
   Participants from JU:Yuzaburo Shimizu, Akihide Kondo (Department of Neurosurgery)
   Participants from MDA:Shoudong Li, Frederick Lang (Department of Neurosurgery)
2. Expression and subcellular localization of MUC21 glycoforms in cancer tissues and their clinicopathological evaluation using tissue arrays.
   (JU / MDA collaboration, ongoing)
   Participant from MDA: Junya Fujimoto (Translational Molecular Pathology)
   Participants from JU: Tatsuro Irimura (Biochemistry and Breast Surgery), Kaori Denda-Nagai (Medical Education), and Miki Noji (Breast Surgery)
3. Are galectins involved with MUC21-driven resistance against apoptosis ?
   (JU / MDA collaboration, ongoing)
   Participants from MDA: Robert Bresalier and Maggie Hafley (Gastrointestinal Research Laboratory of the Department of Gastroenterology, Hematology & Nutrition)
   Participants from JU: Tatsuro Irimura (Biochemistry and Breast Surgery), Kaori Denda-Nagai (Medical Education), and Miki Noji (Breast Surgery)
4. Bcl-2 as a novel molecular target of FLT3-ITD AML with acquired TKD mutation.
   (JU / MDA / RIKEN collaboration, ongoing)
   Participants from MDA: Marina Konopleva and Michael Andreeff (Department of Leukemia)
   Participants from JU: Kotoko Yamatani and Yoko Tabe (Department of Laboratory Medicine)
   Participants from RIKEN:Yoshihide Hayashizaki (RIKEN Center for Life Science Technologies)
5. Mitochondrial transfer confers microenvironment-mediated resistance to OxPhos inhibition in AML
   (JU / MDA / RIKEN collaboration, ongoing)
   Participants from MDA: Marina Konopleva and Michael Andreeff (Department of Leukemia), Joseph R.Marszalek (Institute for Applied Cancer Science)
   Participants from JU: Yoko Tabe (Department of Laboratory Medicine)
   Participants from RIKEN: Yoshihide Hayashizaki (RIKEN Center for Life Science Technologies)
   
6. Utilization of Cap Analysis of Gene Expression (CAGE) sequencing to reveal the alterations of the transcript signatures which contribute to survival of leukemia.
   (JU / MDA / RIKEN collaboration, ongoing)
   Participants from MDA: Marina Konopleva and Michael Andreeff (Department of Leukemia),
   Participants from JU: Yoko Tabe (Department of Laboratory Medicine)
   Participants from RIKEN: Yoshihide Hayashizaki (RIKEN Center for Life Science Technologies)
7. Bone marrow adipocytes facilitate fatty acid oxidation activating AMPK and a transcriptional network supporting survival of acute monocytic leukemia cells
   (JU / MDA collaboration, completed)
   Participants from MDA: Michael Andreeff and Marina Konopleva (Department of Leukemia)
   Participants from JU: Yoko Tabe (Department of Laboratory Medicine)
   
8. Roles of lectins and mucins in cancer cell resistance to therapeutic intervention.
   (JU / MDA collaboration, ongoing)
   Participants from MDA: Robert Bresalier, Margarete Hafley, (Department of Medicine)
   Participants from JU: Tatsuro Irimura, Kaori Denda-Nagai, Haruhiko Fujihira, Miki Noji (Division of Glycobiologics, Intractable Disease Research Center)
9. Inhibition of mTORC1/C2 improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome-like acute B-cell lymphoblastic leukemia.
   (JU / MDA collaboration, completed )
   Participants from MDA: Zhang Q, Shi C, Han L, Marina Konopleva (Department of Leukemia)
   Participants from JU: Yoko Tabe (Department of Laboratory Medicine)
10. Use of glycoform-specific novel anti-mucin monoclonal antibodies in precision medicine.
    (JU / MDA collaboration, ongoing )
    Participants from MDA: Junya Fujimoto, Ignacio Ivan Wistuba (Department of Translational Molecular Pathology)
    Participants from JU: Tatsuro Irimura, Kaori Denda-Nagai, Haruhiko Fujihira, Miki Noji (Division of Glycobiologics, Intractable Disease Research Center)

    ( 2014 April - 2017 July )

11. Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1
    (JU / MDACC collaboration, completed)
    Participants from JU: Kazumasa Sekihara, Yoko Tabe (Department of Laboratory Medicine)
    Participants from MDA: Marina Konopleva, Michael Andreeff (Department of Leukemia)
    
12. ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
    (MDA / JU collaboration, completed)
    Participants from MDA: Jo Ishizawa, Michael Andreeff, Marina Konopleva (Department of Leukemia)
    Participant from JU: Yoko Tabe (Department of Laboratory Medicine)
13. Therapeutic targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein by the selective inhibitor of nuclear export (SINE) XPO1 antagonists as a novel cancer treatment strategy.
    (JU / MDACC collaboration, completed)
    Participants from MDA: Kensuke Kojima, Jo Ishizawa, Marina Konopleva, Michael Andreeff (Department of Leukemia)
    Participants from JU: Yoko Tabe (Department of Laboratory Medicine), Kazuno S, Fujimura T, Ueno T (Laboratory of Molecular and Biochemical Research Support Center)
    
14. Targeting EZH2 upstream kinases for triple negative breast cancer therapy
    (JU / MDACC collaboration, completed)
    Participants from JU: Katsuya Nakai, Mitsue Saito (Department of Breast Oncology)
    Participants from MDA: Hirohito Yamaguch, Mien-Chie Hung (Department of Molecular Cellular Oncology)
15. The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.
    (JU / MDACC collaboration, completed)
    Participants from MDACC: Juliana Benito, Marina Konopleva (Department of Leukemia)
    Participants from JU: Masako Harada (Research Institute for Environmental and Gender Specific Medicine), Yoko Tabe (Department of Laboratory Medicine)
    
16. Integrative genomic and proteomic analyses identifies glycerol-3-phosphate acyltransferase as a target of low-dose ionizing radiation in EBV infected-B cells.
    (JU / MDACC collaboration, completed)
    Participants from JU: Mayumi Nakashiro, Keisuke Sasai (Department of Radiology)
    Kazumasa Sekihara, Yoko Tabe, Takashi Miida (Department of Laboratory Medicine)
    Participants from MDACC: Michael Andreeff, Marina Konopleva (Department of Leukemia)
    
17. Class IA PI3K inhibition inhibits cell growth and proliferation in mantle cell lymphoma.
    (JU / MDACC collaboration, completed)
    Participants from JU: Linhua Jin, Yoko Tabe (Department of Laboratory Medicine)
    Participants from MDACC: Michael Andreeff, Marina Konopleva (Department of Leukemia)